Primary Cells Market was valued at USD 1,716.8 million in 2022 and is poised to grow at a CAGR of 10.8% over 2023-2029. Primary cells in biology refers to cells directly taken from living organisms, as opposed to cell lines that have been cultured for extended period and are often used in various biological and medical research applications. The increased demand for potential cancer medicines and treatments by research institutes and companies over cell lines owing to its close resemblance to cells in living organisms, and more accurate representation of cell behavior, function, and responses to stimuli compared to immortalized cell lines. According to Worldwide Cancer Research Fund International, in 2020, an estimated 18.1 million cancer cases around the world with 9.3 million cases in men and 8.8 million in women. Furthermore, an increased need to assess the biological relevance of the toxicity of chemicals, medicines, and compounds, that assist in the detection of potential risks is anticipated to propel the market in upcoming years. Additionally, the advancements and developments in automation, single-cell analysis, and imaging technologies have created opportunities for more comprehensive and detailed studies using primary cells among researchers and drug development companies. Currently, Organ-on-a-Chip technology is becoming popular in the market and involves the recreation of organ-level functions using primary cells on microfluidic devices, enabling more accurate physiological modeling. For instance, in June 2022, CN Bio Innovations launched an organ-on-a-chip device that allows scientists to test potential drugs on living human organ models in conventional cell culture labs without the need for animal models. But the limited availability of certain cell types, and fresh samples owing to cell source limitations along with a limited lifespan in culture may hinder the market growth. However, the rise in pharmaceutical & biotechnology industries, increase in investments by government initiatives, and private firms, and improvement in infrastructure are anticipated to burgeon the market growth during the forecast years.
Fastest Growing Market
The market is expected to rise due to increased requirement for preclinical and investigative biological research including research on intracellular and extracellular communication, the biology of development, and the mechanisms underlying diabetes, Parkinson's disease, and cancer drives the human primary cells market. Furthermore, the limitation of physiological relevance in studies by the continuous passage of cell lines makes human primary cells a more preferred option for researchers and scientists to generate meaningful data that is more predictive of in vivo outcomes. Additionally, the ongoing recent developments, launch, and approval of several products by key companies has led to a surge in market demand. For instance, in April 2023, the Gamida Cell product "Omisirge" (formerly known as Omidubicel and NiCord) received FDA approval. This is the first FDA market approval of an "expanded" cord blood product, which implies the cord blood has been cultivated in a lab to increase the number of cells in a certain way and so make up for the lack of blood-forming stem cells in a cord blood unit.
The primary cells market valued at USD 1,716.8 million in 2022 and is expected to grow at 10.8% CAGR over the forecast period 2023 – 2029.
The advancements and developments in automation, single-cell analysis, and imaging technologies have created opportunities for more comprehensive and detailed studies using primary cells among researchers and drug development companies.
AllCells, ZenBio Inc. (Research Triangle Park NC), PromoCell, Thermo Fisher Scientific Inc., Cell Biologics Inc., STEMCELL Technologies Inc., Merck KGaA, American Type Culture Collection (ATCC), AG, ATCC, FUJIFILM Irvine Scientific, Inc., Mattek, Axol Bioscience Ltd., Corning Incorporated, and Danaher are a few companies operating in primary cells market.
North America dominates the market with 11.2% CAGR in 2022, and is anticipated to grow with 12.0% CAGR over the forecast period 2023-2029.